CS-2023

CS-2023 is an investigational meningococcal vaccine currently under development by CanSino Biologics. It is designed to provide active immunization against *Neisseria meningitidis*, the bacterium responsible for invasive meningococcal disease, which can manifest as life-threatening meningitis or septicemia. CanSino Biologics already markets two other meningococcal conjugate vaccines: Menhycia (a quadrivalent ACWY conjugate vaccine) and Menphecia (a bivalent AC conjugate vaccine). CS-2023 is a distinct candidate in their pipeline aimed at expanding their coverage or improving upon existing formulations. While specific details regarding its serogroup composition (e.g., whether it targets Serogroup B or is a pentavalent ABCWY formulation) and its specific vaccine platform have not been fully disclosed in public corporate summaries, it is positioned as a key part of the company's strategic focus on bacterial meningitis prevention and was listed in the pre-clinical stage in recent company reports.